

# Avalo Therapeutics, Inc. (AVTX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001534120


| Avalo Therapeutics, Inc.<br>AVTX; healthcare |                                                                                                                                                                                                                   |
|----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Grade                                        | <div> <div>B</div> <div> <div>A</div> <div>B</div> <div>C</div> <div>D</div> <div>E</div> </div> </div> <p>second fifth of 371 graded peers<br/>percentile 23.8; sampling error 2.5 points; lower is stronger</p> |
| Rank                                         | 89 of 371                                                                                                                                                                                                         |
| Profitability                                | <div> <div>A/B</div> <div> <div></div> <div></div> <div></div> <div></div> <div></div> </div> </div> <p>percentile 21.9</p>                                                                                       |
| Solvency                                     | <div> <div>B</div> <div> <div></div> <div></div> <div></div> <div></div> <div></div> </div> </div> <p>percentile 34.4</p>                                                                                         |
| Growth and financing                         | <div> <div>D</div> <div> <div></div> <div></div> <div></div> <div></div> <div></div> </div> </div> <p>percentile 63.7</p>                                                                                         |
| Reliability                                  | <p>0.83 AUC</p> <p>filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025</p>                                                                                                  |
| Peer failure rate                            | <p>1.07% a year</p> <p>Item 1.03 bankruptcies, same asset band, 2012 to 2025</p>                                                                                                                                  |
| Size band                                    | <p>\$12.5M to \$120M assets</p> <p>total assets \$116.5M</p>                                                                                                                                                      |
| Standard universe                            | <p>outside</p> <p>revenue above \$1M and assets above \$10M</p>                                                                                                                                                   |
| Warnings                                     | <p>dilution, degenerate inputs</p> <p>not computable: fortress balance sheet</p>                                                                                                                                  |
| Inputs computable                            | 7 of 14                                                                                                                                                                                                           |
| Graded from                                  | <p>filings received through Mar 23, 2026</p> <p>200 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026</p>                                                                                  |
| Last close                                   | <p>\$13.43</p> <p>2026-10-08; market equity \$720.0M</p>                                                                                                                                                          |
| Price used in grade                          | None                                                                                                                                                                                                              |



**B, the elk**  
second fifth of its sector; letters are fifths of the 371 graded peers

## Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: E from Mar 21, 2022, B from Aug 21, 2026, A/B from Sep 26, 2026, B from Oct 3, 2026

## Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



## Business, in the company's words

opening of Item 1 of the 10-K received Mar 23, 2026

We are a clinical stage biotechnology company fully dedicated to developing IL-1?-based treatments for immune-mediated inflammatory diseases. Our lead product candidate, abdakibart (AVTX-009), an anti-IL-1? monoclonal antibody ("mAb") is in a Phase 2 clinical trial for hidradenitis suppurativa ("HS"). We are also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. Our current focus is on completing the Phase 2 ("LOTUS") trial

evaluating abdakibart (AVTX-009) in HS, preparing for the anticipated topline data readout in the second quarter of 2026, and planning for our Phase 3 trial(s).

## The fourteen inputs


*lower percentile is stronger; equal-weighted sleeves*

| Input                                               | Percentile, 0 to 100 | Value          | Peer median | Percentile | Peers | Period end                                                                |
|-----------------------------------------------------|----------------------|----------------|-------------|------------|-------|---------------------------------------------------------------------------|
| <b>Profitability, sleeve percentile 21.9</b>        |                      |                |             |            |       |                                                                           |
| Gross profitability                                 |                      | not computable | 32.2%       |            |       | latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31 |
| Return on invested capital                          |                      | not computable | 9.3%        |            |       | one or more required annual facts are missing                             |
| Accruals ratio                                      |                      | (20.1%)        | (6.6%)      | 21.9       | 811   | 2025-12-31                                                                |
| Gross margin stability, five years                  |                      | not computable | 2.8 pts     |            |       | latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31 |
| <b>Solvency, sleeve percentile 34.4</b>             |                      |                |             |            |       |                                                                           |
| Twelve-month failure probability                    |                      | 0.03%          | 0.07%       | 21.9       | 248   | 2026-06-30                                                                |
| Altman Z double-prime                               |                      | (8.95)         | (0.31)      | 59.7       | 756   | 2025-12-31                                                                |
| Net debt to EBITDA                                  |                      | not computable | 1.82x       |            |       | one or more required annual facts are missing                             |
| Interest coverage                                   |                      | not computable | (4.51x)     |            |       | one or more required annual facts are missing                             |
| Current ratio                                       |                      | 8.14x          | 2.96x       | 21.7       | 839   | 2025-12-31                                                                |
| <b>Growth and financing, sleeve percentile 63.7</b> |                      |                |             |            |       |                                                                           |
| Revenue growth, three-year compound                 |                      | (85.2%)        | 10.0%       | 99.5       | 415   | 2025-12-31                                                                |
| Free cash flow growth, three-year compound          |                      | not computable | 10.9%       |            |       | current FCF must be positive and base FCF must exceed \$100,000           |
| Reinvestment rate                                   |                      | not computable | 37.1%       |            |       | required facts have no common fiscal period end                           |
| Asset growth, three years                           |                      | 51.7%          | 2.1%        | 7.3        | 704   | 2025-12-31                                                                |
| Net share issuance, one year                        |                      | 113.5%         | 2.5%        | 84.2       | 634   | 2026-03-18                                                                |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check             | Measured                                                              |
|-------------------|-----------------------------------------------------------------------|
| Dilution          | split-adjusted year-over-year share growth is 113.5%                  |
| Degenerate inputs | latest revenue or assets are at or below the \$100,000 validity floor |



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

| Rank | Company                                | Percentile | Letter | Warnings                                 |
|------|----------------------------------------|------------|--------|------------------------------------------|
| 84   | Rhythm Pharmaceuticals, Inc. (RYTM)    | 22.4       | A/B    |                                          |
| 85   | Puma Biotechnology, Inc. (PBYI)        | 22.7       | B      | fortress<br>balance sheet                |
| 86   | Warby Parker Inc. (WRBY)               | 23.0       | B      |                                          |
| 87   | Cronos Group Inc. (CRON)               | 23.2       | B      |                                          |
| 88   | Guardant Health, Inc. (GH)             | 23.5       | B      |                                          |
| 89   | Avalo Therapeutics, Inc. (AVTX) <      | 23.8       | B      | dilution,<br>degenerate<br>inputs        |
| 90   | Sarepta Therapeutics, Inc. (SRPT)      | 24.1       | B      |                                          |
| 91   | Pulmonx Corp. (LUNG)                   | 24.3       | B      | fortress<br>balance sheet                |
| 92   | Amphastar Pharmaceuticals, Inc. (AMPH) | 24.6       | B      |                                          |
| 93   | Mannatech Inc. (MTEX)                  | 24.9       | B      | late filer,<br>fortress<br>balance sheet |
| 94   | NeuroPace Inc. (NPCE)                  | 25.1       | B      |                                          |

What the price implies

at the 2026-10-08 close; none enters the grade

| Measure                                                 | Value   | Peer median | Percentile |
|---------------------------------------------------------|---------|-------------|------------|
| Twelve-month price change, skipping the latest month    | 52.2%   | 8.0%        | 77         |
| Distance from 52-week high                              | (41.3%) | (31.4%)     | 37         |
| EBIT to enterprise value                                | (11.2%) | (1.5%)      | 31         |
| Free cash flow yield                                    | (3.7%)  | (1.0%)      | 42         |
| Book value to price                                     | 0.62    | 0.28        | 75         |
| Sales to price                                          | 0.00    | 0.31        | 1          |
| Composite equity issuance, five years                   | 745.8%  | 20.3%       | 99         |
| Relative strength against the sector, log excess return | 0.21    | (0.14)      | 77         |

Diagnostics

not in the grade

| Measure                                            | Value |
|----------------------------------------------------|-------|
| Piotroski F-score None of 9, period end 2025-12-31 |       |
| Return on assets above zero                        | fail  |
| Operating cash flow above zero                     | fail  |
| Return on assets improved                          | pass  |
| Operating cash flow exceeds net income             | pass  |
| Long-term leverage fell                            | fail  |
| Current ratio improved                             | fail  |
| No new shares issued                               | fail  |
| Gross margin improved                              | fail  |

|                                         |                                |
|-----------------------------------------|--------------------------------|
| Asset turnover improved                 | fail                           |
| <b>Cash, filings, liquidity</b>         |                                |
| Cash and equivalents                    | \$85.4M                        |
| Operating cash flow, four quarters      | -\$68.3M                       |
| Months of runway                        | 15.0                           |
| Days since last periodic filing         | 64 (10-Q received Aug 6, 2026) |
| Median daily dollar volume, 63 sessions | \$14.4M                        |

## Sources

each row links to the filing index on sec.gov

| #  | Concept             | XBRL tag                                                    | Value      | Period end | Received   | Form | Accession            |
|----|---------------------|-------------------------------------------------------------|------------|------------|------------|------|----------------------|
| 1  | revenue             | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | \$1.9M     | 2023-12-31 | 2025-03-20 | 10-K | 0001628280-25-013986 |
| 2  | cost of revenue     | us-gaap:CostOfGoodsAndServicesSold                          | \$1.3M     | 2023-12-31 | 2024-03-29 | 10-K | 0001628280-24-013786 |
| 3  | assets              | us-gaap:Assets                                              | \$21.0M    | 2023-12-31 | 2025-03-20 | 10-K | 0001628280-25-013986 |
| 4  | net income          | us-gaap:NetIncomeLoss                                       | -\$78.3M   | 2025-12-31 | 2026-03-23 | 10-K | 0001534120-26-000011 |
| 5  | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities          | -\$51.5M   | 2025-12-31 | 2026-03-23 | 10-K | 0001534120-26-000011 |
| 6  | assets              | us-gaap:Assets                                              | \$116.5M   | 2025-12-31 | 2026-03-23 | 10-K | 0001534120-26-000011 |
| 7  | assets              | us-gaap:Assets                                              | \$150.7M   | 2024-12-31 | 2026-03-23 | 10-K | 0001534120-26-000011 |
| 8  | revenue             | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | \$18.1M    | 2022-12-31 | 2024-03-29 | 10-K | 0001628280-24-013786 |
| 9  | cost of revenue     | us-gaap:CostOfGoodsAndServicesSold                          | \$3.4M     | 2022-12-31 | 2024-03-29 | 10-K | 0001628280-24-013786 |
| 10 | revenue             | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | \$5.4M     | 2021-12-31 | 2023-03-29 | 10-K | 0001628280-23-009630 |
| 11 | cost of revenue     | us-gaap:CostOfGoodsAndServicesSold                          | \$1.5M     | 2021-12-31 | 2023-03-29 | 10-K | 0001628280-23-009630 |
| 12 | revenue             | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | \$6.7M     | 2020-12-31 | 2022-03-02 | 10-K | 0001628280-22-004671 |
| 13 | cost of revenue     | us-gaap:CostOfGoodsAndServicesSold                          | \$300,000  | 2020-12-31 | 2022-03-02 | 10-K | 0001628280-22-004671 |
| 14 | revenue             | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | \$6.8M     | 2019-12-31 | 2021-03-08 | 10-K | 0001628280-21-004162 |
| 15 | cost of revenue     | us-gaap:CostOfGoodsAndServicesSold                          | -\$566,523 | 2019-12-31 | 2020-03-11 | 10-K | 0001628280-20-003395 |
| 16 | current assets      | us-gaap:AssetsCurrent                                       | \$105.3M   | 2025-12-31 | 2026-03-23 | 10-K | 0001534120-26-000011 |
| 17 | current liabilities | us-gaap:LiabilitiesCurrent                                  | \$12.9M    | 2025-12-31 | 2026-03-23 | 10-K | 0001534120-26-000011 |
| 18 | retained earnings   | us-gaap:RetainedEarningsAccumulatedDeficit                  | -\$448.5M  | 2025-12-31 | 2026-03-23 | 10-K | 0001534120-26-000011 |
| 19 | operating income    | us-gaap:OperatingIncomeLoss                                 | -\$72.9M   | 2025-12-31 | 2026-03-23 | 10-K | 0001534120-26-000011 |
| 20 | book equity         | us-gaap:StockholdersEquity                                  | \$83.0M    | 2025-12-31 | 2026-03-23 | 10-K | 0001534120-26-000011 |
| 21 | liabilities         | us-gaap:Liabilities                                         | \$33.4M    | 2025-12-31 | 2026-03-23 | 10-K | 0001534120-26-000011 |
| 22 | revenue             | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | \$59,000   | 2025-12-31 | 2026-03-23 | 10-K | 0001534120-26-000011 |
| 23 | revenue             | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | \$441,000  | 2024-12-31 | 2026-03-23 | 10-K | 0001534120-26-000011 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities          | -\$26.8M   | 2022-12-31 | 2024-03-29 | 10-K | 0001628280-24-013786 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment          | \$95,000   | 2022-12-31 | 2023-03-29 | 10-K | 0001628280-23-009630 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities          | -\$70.9M   | 2021-12-31 | 2023-03-29 | 10-K | 0001628280-23-009630 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment          | \$113,000  | 2021-12-31 | 2023-03-29 | 10-K | 0001628280-23-009630 |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities          | -\$40.5M   | 2020-12-31 | 2022-03-02 | 10-K | 0001628280-22-004671 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment          | \$63,000   | 2020-12-31 | 2022-03-02 | 10-K | 0001628280-22-004671 |
| 30 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities          | -\$19.1M   | 2019-12-31 | 2021-03-08 | 10-K | 0001628280-21-004162 |
| 31 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment          | \$262,013  | 2019-12-31 | 2021-03-08 | 10-K | 0001628280-21-004162 |
| 32 | assets              | us-gaap:Assets                                              | \$33.4M    | 2022-12-31 | 2024-03-29 | 10-K | 0001628280-24-013786 |
| 33 | shares outstanding  | dei:EntityCommonStockSharesOutstanding                      | 22,788,452 | 2026-03-18 | 2026-03-23 | 10-K | 0001534120-26-000011 |
| 34 | shares outstanding  | dei:EntityCommonStockSharesOutstanding                      | 10,671,934 | 2025-03-17 | 2025-03-20 | 10-K | 0001628280-25-013986 |